Mogam Institute for Biomedical Research

The Green Cross Corporation

Ki Su Kim

Eun Jung Song

Jong Wha Won

Hyung Kwon Lim

Hye Ji Choi

Mijung Lee

Dong Sik Kim

Yun Jung Lee

Ok Jae Lim

Ki Joon Cho

Ae Rin Yoon

Eui Cheol Cho

Yang Mi Lim

Jun Hong Jeong

Jung Hong Jeong

Yong Yea Park

Kwan Yub Kang

An asymmetric fusion protein in which a fragment of an antibody binding to an insulin receptor, an iduronate-2-sulfatase (IDS) enzyme, and an Fc region are fused, and a use thereof are disclosed. The fusion protein can cross the blood-brain barrier (BBB) to deliver the IDS enzyme to the brain. Therefore, a pharmaceutical composition containing the fusion protein as an active ingredient can be used as a therapeutic agent for a central nervous system disease and particularly, is expected to prevent and treat various diseases caused by ribosome accumulation.

Fusion protein comprising IDS and use thereof

The present invention relates to an anti-CD3 antibody and a pharmaceutical composition for cancer treatment comprising same. The antibody according to the present invention has high affinity and specificity for CD3 and thus can be effectively used in cancer prevention or treatment.

Anti-CD3 antibody and pharmaceutical composition for cancer treatment comprising same

The present invention relates to an anti-MSLN antibody and a pharmaceutical composition for cancer treatment comprising same. The anti-MSLN antibody according to the present invention has high affinity and specificity for MSLN and thus can be effectively used in cancer prevention or treatment.

Anti-MSLN antibody and pharmaceutical composition for cancer treatment comprising same

Growing community of inventors

Yongin-si, South Korea

Ki Su Kim